Basimglurant
Basimglurant (developmental code names RG7090, RO4917523) is an experimental drug compound that is being researched for its potential use in the treatment of major depressive disorder (MDD). It functions as a negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5). Despite promising results in early clinical trials, its development for the treatment of MDD has seen various challenges.
Mechanism of Action[edit | edit source]
Basimglurant operates by modulating the mGluR5 receptor, which is a type of glutamate receptor. Glutamate is the most abundant excitatory neurotransmitter in the vertebrate nervous system, and its receptors are implicated in a variety of neurological and psychiatric conditions. By acting as a negative allosteric modulator, basimglurant decreases the receptor's sensitivity to glutamate, potentially correcting the glutamatergic dysfunction believed to be associated with MDD.
Clinical Trials[edit | edit source]
Initial clinical trials of basimglurant showed promise in treating MDD, with the drug demonstrating an ability to improve depressive symptoms without many of the side effects associated with traditional antidepressants. However, subsequent studies yielded mixed results, leading to a reevaluation of its development path.
Potential Benefits and Challenges[edit | edit source]
One of the potential benefits of basimglurant is its novel mechanism of action, which differs from that of traditional antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). This could make it a valuable option for patients who do not respond to existing treatments. However, the challenges in its development, including inconsistent clinical trial outcomes, highlight the complexities of treating MDD and the need for further research.
Current Status[edit | edit source]
As of the last update, the development of basimglurant for the treatment of MDD has been paused or discontinued. The drug's future in this indication remains uncertain, and it serves as a case study in the difficulties of developing new psychiatric medications.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
